Donate
Australian & New Zealand Childrens Haematology/Oncology Group

ANZCHOG Children’s Cancer Clinical Trials Repository

Study Title
A Multicenter, Open-label Phase 1b Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients with Unresectable or Metastatic BRAF V600-mutant Melanoma
Protocol ID
ARRAY-162-115
Disease (Sub Disease)
Solid tumours
Diagnosis Stage
New diagnosis
Relapse/refractory
Location
NSW, VIC
Sponsor
Pfizer
Collaborators
Pierre Fabre Laboratories
Trial Status
Open
Sites
The Children's Hospital at Westmead
Monash Children's Hospital
Sydney Children's Hospital
Study Type
Treatment
Phase
Phase 1
Age Eligibility
12 Years to 17 Years
International registry ID's
NCT03878719
Back to Registry
Study Title A Multicenter Open-label Phase 1b Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients with Unresectable or Metastatic BRAF V600-mutant Melanoma
Protocol ID ARRAY-162-115
Disease (Sub Disease) Solid tumours
Diagnosis Stage New diagnosis
Relapse/refractory
Location NSW / VIC
Sponsor Pfizer
Collaborators Pierre Fabre Laboratories
Links https://clinicaltrials.gov/ct2/show/NCT03878719
Trial Status Open
Trial Open Date 13/08/2020
Sites The Children's Hospital at Westmead / Monash Children's Hospital / Sydney Children's Hospital
Study Type Treatment
Phase Phase 1
Age Eligibility 12 Years to 17 Years
International registry ID's NCT03878719